Canton Strategic Holdings Inc

Tharimmune Inc is a US clinical-stage biotechnology company focused on developing novel therapeutics for immune-mediated and inflammatory diseases. The company addresses significant unmet medical needs in challenging conditions. It aims to improve the outcomes for patients affected by these diseases. Within the healthcare sector, Tharimmune Inc focuses on immunomodulation. It develops small-molecule and RNA interference therapies for conditions such as cholestatic pruritus. The company's efforts provide effective solutions where current treatments are limited. Keep up to date on the latest share price changes by adding THAR stock to your eToro watchlist. This content was generated by artificial intelligence. We cannot guarantee the accuracy, completeness, or timeliness of the information provided.